These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2505604)

  • 41. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A randomized multicenter trial comparing recombinant staphylokinase with recombinant tissue-type plasminogen activator in patients with acute myocardial infarction].
    Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Aug; 35(8):691-6. PubMed ID: 17963623
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
    Levine M; Hirsh J; Weitz J; Cruickshank M; Neemeh J; Turpie AG; Gent M
    Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens.
    Eppler S; Senn T; Gilkerson E; Modi NB
    Biopharm Drug Dispos; 1998 Jan; 19(1):31-8. PubMed ID: 9510983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
    Collen D; Bounameaux H; De Cock F; Lijnen HR; Verstraete M
    Circulation; 1986 Mar; 73(3):511-7. PubMed ID: 2419009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.
    Nagao K; Satou K; Watanabe I; Arima K; Yamashita M; Ooiwa K; Kanmatsuse K
    Jpn Circ J; 1998 Feb; 62(2):111-4. PubMed ID: 9559429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction.
    Tranchesi B; Chamone DF; Cobbaert C; Van de Werf F; Vanhove P; Verstraete M
    Am J Cardiol; 1991 Jul; 68(2):161-5. PubMed ID: 1829574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
    Van de Werf F; Lijnen HR; Collen D
    Coron Artery Dis; 1993 Oct; 4(10):929-33. PubMed ID: 8269200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
    Kostis JB; Dockens RC; Thadani U; Bethala V; Pepine C; Leimbach W; Vachharajani N; Raymond RH; Stouffer BC; Tay LK; Shyu WC; Liao WC
    Clin Pharmacokinet; 2002; 41(6):445-52. PubMed ID: 12074692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients.
    Gibelin P; Tiger F; Moles V; Bossan S; Blanc P; Baudouy M; Morand P
    Cardiovasc Drugs Ther; 1992 Aug; 6(4):373-7. PubMed ID: 1520647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction.
    Verstraete M; Bleifeld W; Brower RW; Charbonnier B; Collen D; de Bono DP; Dunning AJ; Lennane RJ; Lubsen J; Mathey DG
    Lancet; 1985 Nov; 2(8462):965-9. PubMed ID: 2865502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction.
    McNeill AJ; Cunningham SR; Flannery DJ; Dalzell GW; Wilson CM; Campbell NP; Khan MM; Patterson GC; Webb SW; Adgey AA
    Br Heart J; 1989 Apr; 61(4):316-21. PubMed ID: 2496740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.
    Seifried E; Tanswell P; Ellbrück D; Haerer W; Schmidt A
    Thromb Haemost; 1989 Jun; 61(3):497-501. PubMed ID: 2508258
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
    DeWood MA; Kurnik PB; Jolly MK; Jain AC; Khaja F; Gorfinkel HJ; Morris DL; Satler L; LittleJohn J
    Clin Cardiol; 1993 Apr; 16(4):302-10. PubMed ID: 8458110
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
    Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
    Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alteplase: a tissue plasminogen activator for acute myocardial infarction.
    Zeller FP; Spinler SA
    Drug Intell Clin Pharm; 1988 Jan; 22(1):6-14. PubMed ID: 3127186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty.
    Ruocco NA; Currier JW; Jacobs AK; Ryan TJ; Faxon DP
    Am J Cardiol; 1991 Dec; 68(17):1609-13. PubMed ID: 1746461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
    De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
    Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.